Insulet Corporation $PODD Holdings Lessened by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. lowered its position in Insulet Corporation (NASDAQ:PODD – Free Report) by 62.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,821 shares of the medical instruments supplier’s stock after selling 14,530 shares during the period. Landscape Capital Management L.L.C.’s holdings in Insulet were worth $1,151,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. BlackRock Inc. purchased a new position in shares of Insulet during the second quarter worth $1,018,582,000. Arrowstreet Capital Limited Partnership boosted its holdings in Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the last quarter. Man Group plc purchased a new stake in Insulet in the second quarter valued at $78,746,000. Amundi grew its position in Insulet by 13.6% during the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock worth $77,320,000 after purchasing an additional 60,929 shares during the period. Finally, Bank of America Corp DE purchased a new position in shares of Insulet during the 2nd quarter valued at about $64,921,000.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Royal Bank Of Canada lifted their price target on Insulet from $160.00 to $180.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. UBS Group increased their price target on shares of Insulet from $150.00 to $171.00 and gave the stock a “neutral” rating in a report on Thursday, November 5th. Barclays raised their price target on shares of Insulet from $150.00 to $165.00 and gave the company an “equal weight” rating in a research report on Friday, November 6th. Wells Fargo & Company lifted their price objective on shares of Insulet from $144.00 to $172.00 and gave the company an “equal weight” rating in a report on Thursday, November 5th. Finally, Stifel Nicolaus downgraded shares of Insulet from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $180.00 to $165.00 in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $184.33.

Check Out Our Latest Analysis on Insulet

Insulet Stock Performance

NASDAQ:PODD opened at $137.23 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51. The company has a fifty day moving average of $142.25 and a two-hundred day moving average of $171.25. The stock has a market capitalization of $9.52 billion, a PE ratio of 22.35, a P/E/G ratio of 1.07 and a beta of 1.06. Insulet Corporation has a fifty-two week low of $126.40 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD – Get Free Report) last released its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The business had revenue of $842.00 million during the quarter, compared to analysts’ expectations of $832.63 million. During the same quarter in the previous year, the company earned $1.24 earnings per share. The company’s quarterly revenue was up 19.2% on a year-over-year basis. As a group, research analysts forecast that Insulet Corporation will post 6.76 earnings per share for the current fiscal year.

Insulet Company Profile

(Free Report)

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Featured Stories

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.